Detection of DNA Aberrations in Human Cancers by Single-Strand Conformation Polymorphism Analysis of Polymerase Chain Reaction Products.

Murakami, Yoshinori; Suzuki, Youiohi; Kishimoto, Yosuke; Hirohashi, Setsuo; Hayashi, Kenshi; Sekiya, Takao

doi:10.1620/tjem.168.247

Cited by 8 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To detect the mutation in the TP53 gene, we used the single-strand conformational polymorphism (SSCP) test, under the premise that abnormal electrophoretic migration results from genetic mutation, as previously showed [4,14]. Exons 5–7 of the p53 gene were amplified by PCR using three pairs of the primers described by Murakami et al [14].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

TP53 Codon 72 and Intron 3 Polymorphisms and Mutational Status in Gastric Cancer: An Association with Tumor Onset and Prognosis

Filho¹,

Cordeiro²,

Vieira³

et al. 2012

Pathobiology

View full text Add to dashboard Cite

Although TP53 alterations have been studied in human tumors, data considering the role of two common TP53 polymorphisms (Pro72Arg in codon 72 and Ins16bp in intron 3) and their associations with TP53 mutations in gastric cancer are very limited. Thus, we analyzed these parameters taking into consideration the clinicopathological data. DNA from 106 gastric tumor samples was available for TP53 Pro72Arg and TP53 Ins16bp polymorphism genotyping by PCR-RFLP and PCR, respectively. The mutational status of the TP53 exons 5–7 was assessed by the single-strand conformational polymorphism test. The TP53 72ArgArg genotype was statistically associated with patients aged ≥65 years (p = 0.039), and the intron 3 A2A2 genotype was correlated with late-stage tumors (III and IV; p = 0.043). Considering both polymorphisms, a negative correlation between the TP53 Pro-A1 haplotype and age <65 years (r = –0.211; p = 0.030) was found. Taking into account the TP53 mutations, the Pro/Pro genotype was positively correlated with the presence of exon 7 mutations (p = 0.049), and a correlation between this genotype and the number of mutations in TP53 was observed (p = 0.019). This study corroborates the understanding of TP53 polymorphisms in gastric carcinogenesis, especially regarding the genetic features in tumor onset and prognosis.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Exons 5–7 of the p53 gene were amplified by PCR using three pairs of the primers described by Murakami et al [14]. Each PCR reaction for a total of 25 µl final volume consisted of 0.2 mmol/l of the four deoxynucleotide triphosphate, 1.5 mmol/l MgCl 2 , 0.4 µmol/l of each primer and 0.5 units of Taq DNA polymerase (Invitrogen®).…”

Section: Methodsmentioning

confidence: 99%

TP53 Codon 72 and Intron 3 Polymorphisms and Mutational Status in Gastric Cancer: An Association with Tumor Onset and Prognosis

Filho¹,

Cordeiro²,

Vieira³

et al. 2012

Pathobiology

View full text Add to dashboard Cite

show abstract

“…Exons 5-9 of p53 gene were amplified by PCR using four pairs of the primes described by Murakami et al [21] . Each PCR reaction for a total of 25 µL final volume consisted of 0.2 mmol/L of the four deoxynucleotide triphosphate, 1.5 mmol/L MgCl 2 , 0.4 µmol/L of each primer and 0.5 U of Taq DNA polymerase (Invitrogen ® ).…”

Section: Analysis Of P53 Mutationmentioning

confidence: 99%

H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: Correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression

Lima

Lima²,

André³

et al. 2008

WJG

View full text Add to dashboard Cite

AIM: To investigate the interrelationship betweenH pylori and Epstein-Barr virus (EBV) infection in the gastric carcinogenesis having in focus the p53 mutation and the c-Myc, Bcl-2 and Bax expression.METHODS: seventy-one gastric carcinoma tissues were assessed by polymerase chain reaction (PCR) for H pylori and in situ hybridization for EBV. c-Myc, Bcl-2 and Bax expression were detected by immunohistochemistry and single-stranded conformational polymorphism (SSCP) for p53 mutation. RESULTS:The positivity rates for H pylori and EBV were 94.4% and 8.45%, respectively. The majority of the cases displayed only the H pylori presence. All EBV positive cases were also H pylori positive. None infectious agent was observed in 5.55% of the cases. The intestinal type tumor was more frequent in the co-infected and non-infected groups. The female predominated in the non-infected group showing statistical significance (70.4% vs 29.6%, P = 0.039). The Bcl-2 was only detected in the group exclusively infected by H pylori .However, c-Myc and Bax were detected in the three groups but with a low frequency in the co-infected group. Mutation of p53 was present in all groups, with the highest frequencies in the H pylori positive groups. CONCLUSION:The frequency of H pylori infection in gastric carcinomas was high. The presented data indicated that gastric carcinogenesis has different pathways depending of the presence of the two investigated infectious agents, suggesting a possible involvement of H pylori with apoptotic process. The low expression of c-Myc and Bax in the EBV-positive groups suggests that EBV may inhibit the expression of these proteins. Nevertheless, p53 mutation shows to be a relevant alteration, independent of both infectious agents.

show abstract

“…In particular, p53 mutations have been demonstrated with a satisfactory sensitivity by both DGGE and SSCP analysis [60,107,108]. Although the SSCP technique originally included radioisotopic labelling of PCR fragments, it can be successfully performed using non-radioactive substances (silver stains and fluorochromes) to visualize DNA frgments.…”

Section: Detection Of P53 Aberrations: Immunohistochemistry and Molecmentioning

confidence: 99%

The clinical significance of p53 aberrations in human tumours

Bòsari

Viale

1995

Vichows Archiv A Pathol Anat

View full text Add to dashboard Cite

p53 aberrations are the most common genetic alteration found in human tumours and this review summarizes the current understanding of the clinical significance of p53 abnormalities. Immunohistochemical and molecular techniques can demonstrate alterations at the protein and gene level, respectively, but with a significant discordance between the findings of either technique. The tumours evaluated in this review include cancers of the breast, lung, gastrointestinal tract, genitourinary tract, and others. In most cases, only data on p53 protein are available and in each of these tumour types discrepant conclusions on the clinical value of p53 abnormalities as prognostic indicators have been reached. The role of p53 in the context of anticancer adjuvant therapy has also been analysed. Experimental data suggest that p53 affects the apoptotic response to anticancer agents, but this has not yet been proven in a clinical series where this demonstration and its effect on therapy could represent one of the most important endpoints in p53 clinical research. The use of standardized techniques to evaluate p53 gene mutation and protein accumulation within controlled clinical series of patients entering prospective trials is essential to answer the many remaining questions on the clinical significance of p53 aberrations.

show abstract

Detection of DNA Aberrations in Human Cancers by Single-Strand Conformation Polymorphism Analysis of Polymerase Chain Reaction Products.

Cited by 8 publications

References 15 publications

<b><i>TP53</i></b> Codon 72 and Intron 3 Polymorphisms and Mutational Status in Gastric Cancer: An Association with Tumor Onset and Prognosis

<b><i>TP53</i></b> Codon 72 and Intron 3 Polymorphisms and Mutational Status in Gastric Cancer: An Association with Tumor Onset and Prognosis

H pylori (CagA) and Epstein-Barr virus infection in gastric carcinomas: Correlation with p53 mutation and c-Myc, Bcl-2 and Bax expression

The clinical significance of p53 aberrations in human tumours

Contact Info

Product

Resources

About